Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug...

Atlantic Health System's Gerald J. Glasser Brain Tumor Center, one of four sites in the country, opens phase III study of first-in-class drug VAL-083, which has already shown promise in...(PRWeb January 10, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15074260.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news